TAS::75 0849::TAS CONTINUATION OF FOLLOW-UP OF DES-EXPOSED COHORTS

己烯雌酚（DES）是一种于1938年首次合成的药物，在美国和欧洲被用于预防自然流产和早产的数百万孕妇。1971年，Herbst报道妊娠期间使用DES与暴露于DES的雌性后代阴道透明细胞腺癌（CCA）的发生有很强的相关性。动物模型已经证明DES对子宫内暴露的后代有一系列影响，包括生殖功能障碍、免疫系统改变、行为和性异常，以及雄性和雌性各种生殖癌的增加。NCI与五个现场中心合作，重新组合了先前研究过的des暴露和未暴露的母亲、女儿和儿子队列，并通过队列中的家族联系确定了以前未研究过的有记录的暴露状态的受试者。标准化的基线问卷邮寄给队列成员，以确定癌症和其他疾病的风险。收集报告的癌症和肿瘤前病变的病理报告。已经进行了三个不同阶段的后续工作。本研究的目的是通过邮寄问卷和收集病历的方式继续进行随访，这在研究的第一阶段就开始了。人们开始担心，接触des的女儿患乳腺癌的风险可能更高。在子宫内暴露于高水平的内源性雌激素被认为会增加患乳腺癌的风险，而DES是一种有效的雌激素。这些儿子患癌症的风险也将继续评估，特别是前列腺癌风险的增加。由于在子宫内暴露于DES的后代目前已接近40岁，癌症发病率开始上升，因此继续对这些队列进行随访以确定癌症风险是否长期增加是很重要的。

Diethylstilbestrol (DES), a drug first synthesized in 1938, was administered to several million pregnant women in the U.S. and Europe for the prevention of spontaneous abortion and premature delivery. In 1971, Herbst reported a strong association between DES use in pregnancy and the occurrence of vaginal clear cell adenocarcinoma (CCA) in exposed female offspring. Animal models have demonstrated a range of DES effects on offspring exposed in utero, including reproductive dysfunction, immune system changes, behavioral and sexual abnormalities, and increases in various reproductive cancer in males and females. NCI, in collaboration with five field centers, reassembled previously studied cohorts of DES-exposed and unexposed mothers, daughters and sons, and identified subjects with documented exposure status who had not been studied previously, through familial links within the cohorts. Standardized baseline questionnaires were mailed to cohort members to ascertain the risk of cancer and other disorders. Pathology reports were collected for reported cancers and preneoplastic conditions. Three separate phases of follow-up have been conducted. The purpose of this study is to continue the follow-up, by means of mailed questionnaires and medical record collection, which was begun during the the first phase of the study. Concern has arisen that DES-exposed daughters may be at higher risk of breast cancer. Exposure to high levels of endogenous estrogen in utero has been hypothesized to increase the risk of breast cancer and DES is a potent estrogen. Cancer risk in the sons will also continue to be assessed, especially for increased risks of prostate cancer. since the offspring who were exposed to DES in utero are currently reaching their late forties, when cancer rates begin to rise, it is important to continue the follow-up of these cohorts to determine if there are long-term increases in cancer risk.